Heparanase 2 emerges as key protector of blood vessel integrity
An international research team led by MDI Biological Laboratory President Hermann Haller, M.D. and postdoctoral researcher Yannic Becker,…
Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major…